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Summary  
Background: Survivors of childhood cancers are at risk of developing subsequent primary 
leukemias (SPLs), but the long-term risks after beyond 20 years following treatment are still 
unclear. We investigated the risk of SPLs in five-year childhood cancer survivors using a large-
scale pan-European (PanCareSurFup) cohort and evaluated variations in the risk by cancer 
and demographic factors. 
Methods: This largest-ever assembled cohort comprises 69,460 five-year childhood cancer 
survivors from 12 European countries. Standardized incidence ratios (SIRs) and absolute 
excess risks (AERs) were calculated.  
Results: One hundred and fifteen survivors developed a SPL including 86 myeloid leukemias 
(SPML), 17 lymphoid leukemias and 12 other types of leukemias; of these SPLs, 31(27%) 
occurred beyond 20 years from first childhood cancer diagnosis. Compared with the general 
population, childhood cancer survivors had a 4-fold increased risk (SIR = 3.7, 95% confidence 
interval [CI]: 3.1 to 4.5) of developing leukemia, and eight leukemias per 100,000 person-years 
(AER = 7.5, 95% CI: 6.0 to 9.2) occurred in excess of that expected. The risks remained 
significantly elevated beyond 20 years from first primary malignancy (SIR = 2.4, 95% CI: 1.6 
to 3.4). Overall, the risk ratio for SPML (SIR = 5.8, 95% CI: 4.6 to 7.1) was higher than that for 
other SPLs. 
Conclusions: We demonstrate that beyond 20 years after childhood cancer diagnosis, 
survivors experience an increased risk for SPLs compared to that expected from the general 
population. Our findings highlight the need for awareness by survivors and their health care 
providers for potentially risk related to SPL.  
 
Keywords: Childhood cancer survivors; second cancers; subsequent primary leukemia; 
myeloid leukemias; lymphoid leukemias.  
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Introduction 
The survival of children with cancer has improved significantly over the past 60 years, with 
more than 80% of individuals diagnosed recently becoming five-year survivors.1 Nevertheless, 
significant long-term morbidities continue to impact the majority of children who survived 
cancer. One of the most devastating sequelae among childhood cancer survivors (CCSs) is 
the occurrence of subsequent primary neoplasms.2-8 Given that the number of survivors 
continues to increase, it is imperative that studies are undertaken to improve the 
understanding of the risks and causes of such late effects of treatments for cancer in order to 
produce an evidence base to inform clinical guidelines for follow-up. 
Subsequent primary leukemias (SPLs), both myeloid and lymphoid leukemias, are a concern 
for long-term CCSs. Previous investigations have reported that the cumulative incidence of 
SPLs plateaus between 10 and 15 years after first primary therapy.5,9 To our knowledge, 
information on the risk of developing SPLs after 20 years remains unclear due to inadequate 
statistical power and follow-up time of those previous studies. For example, among 14,358 
five-year survivors from the North American Childhood Cancer Survivor Study cohort, 43 SPLs 
were observed of which only 13 were diagnosed after 15 years from the original cancer 
diagnosis.5 The pan-European cohort of CCSs (PanCareSurFup) from several European 
countries offers a unique opportunity to evaluate the risk of SPL in a large population of 
survivors with a variety of first primary malignancies and long follow-up into adulthood.10-15 The 
principal aim of the current study was to investigate the risk of occurrence of SPLs in five-year 
CCSs using the large-scale PanCareSurFup cohort and evaluate variations in the risk by 
cancer and demographic factors. 
 
Methods 
PanCareSurFup cohort  
The PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies 
(PanCareSurFup; www.pancaresurfup.eu) consortium pools data from 13 European cohorts, 
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within 12 countries, to establish the largest ever collaborative study to comprehensively 
investigate adverse health outcomes in long-term CCSs. The PanCareSurFup cohort 
comprises data from both population-based cancer registries and major treatment centers.12,13 
A total of 69,460 five-year CCSs diagnosed before the age of 20 years between 1940 and 
2008 were included in this cohort as previously described.14,15  
First primary neoplasms (FPN) were grouped according to the International Classification of 
Childhood Cancer third edition.16 Ethical approval was obtained separately for each cohort 
from the appropriate bodies within each specific country. The main characteristics of the 
PanCareSurFup cohort are described in Table 1. 
Identification and ascertainment of SPLs 
Follow-up for SPLs began at the date of five-year survival. Exit from risk was the first of: date 
of SPL; date of death (competing risk); date of last follow-up contact; date lost to follow-up. 
SPLs were coded using the International Classification of Diseases for Oncology (ICD-O) 
Editions 1, 2 and 3,16-18 consistent with other publications analyzing such data (Appendix Table 
S1, p 1).6-8,19,20 These SPLs were ascertained through (or using a combination of): linkage with 
population-based national cancer registries, follow-up clinics, questionnaires, available 
medical records, linkage with national mortality registries, and linkage with health insurance 
registries and validated principally using pathology reports and occasionally other definitive 
diagnostic reports.14,15   
Statistical analyses 
To compare the observed number of SPLs with that expected from the general population, 
general population leukemia incidence rates were classified according to the adolescent and 
young adult cancer classification based on ICD-O morphology. Incidence rates by ICD-O 
morphology were available for the United Kingdom (UK) (years 1971-2006: England and 
Wales, only)21 and were used as general population rates also for France, Hungary, Italy, 
Netherlands, Slovenia and Switzerland. Similarly, Finnish incidence rates by ICD-O 
morphology (years 1953-2011) were used for Denmark, Norway, Sweden and Iceland.22 When 
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the range of calendar years for the general population cancer rates did not cover the entire 
follow up period, rates from the closest available calendar year were used. 
Standardized incidence ratios (SIRs) were calculated as the observed number of SPLs divided 
by the expected number of leukemias. Absolute excess risks (AERs) were calculated as the 
observed minus the expected number of leukemias, divided by person-years at risk and 
multiplied by 100,000. The AER can be interpreted as the number of excess leukemias 
observed beyond that expected from the general population per 100,000 persons per year. 
The 95% confidence intervals (CIs) were calculated assuming that the observed number of 
SPLs followed a Poisson distribution. SIRs and AERs were stratified by country, sex, type of 
childhood cancer, age at and decade of childhood FPN diagnosis, attained age at exit, and 
years of follow-up. Relative risks (RR) and the relative excess risk (RER) of developing SPLs 
associated with these potential explanatory factors were estimated using univariable and 
multivariable Poisson regression. RRs may be interpreted as the ratio of SIRs, adjusted for 
relevant co-factors fitted. Similarly, relative RERs may be interpreted as the ratio of AERs, 
adjusted for relevant co-factors fitted. Tests of homogeneity and trend were based on 
likelihood ratio tests. For trend tests, ordinal variables were treated as continuous variables in 
the model. Lastly, cumulative incidence curves relating to the first occurrence of a SPL, 
adjusting for death as a competing risk, were calculated and Gray's tests were used to 
evaluate hypotheses of equality of cumulative incidence functions between subgroups where 
relevant. All statistical analyses were conducted in SAS software, version 9.4. A two-sided p-
value <0.05 was considered statistically significant. 
 
Results 
Cohort characteristics  
Among 69,460 five-year CCSs, a total of 1,126,273 person-years were accrued and 115 SPLs 
were observed after a median follow-up of 19 years (range 5–67 years) and a median age at 
childhood cancer diagnosis of 7 (range 0–20 years). Loss-to-follow-up did not exceed 6% 
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(Appendix Table S2, p 2). The most commonly observed SPLs were subsequent primary 
myeloid leukemias (SPML) [86 SPMLs including 44 acute myeloid leukemias (AML), 10 
chronic myeloid leukemias (CML) and 32 unspecified/other myeloid leukemias mainly AML 
not otherwise specified (NOS) and myeloid leukemia NOS], followed by subsequent primary 
lymphoid leukemias (SPLL) [17 SPLLs including 5 acute lymphoid leukemias (ALL), 4 chronic 
lymphoid leukemias (CLL) and 8 unspecified/other lymphoid leukemias mainly precursor B-
cell and precursor T-cell lymphoblastic leukemia]; and other types of leukemias [12 SPLs 
including 5 acute leukemias NOS, 2 leukemia NOS, 2 hairy cell leukemia and 3 other 
leukemias] (Appendix Tables S1 and S3, p 1 and 3). Demographic and cancer characteristics 
of the study cohort are shown in Table 1. The median attained age at study exit was 28 years 
(range 5–79 years) and female survivors accounted for 41% of five-year survivors who 
developed a SPL. Of those survivors who developed a SPL, 19 (17%) were originally 
diagnosed with Hodgkin lymphoma as childhood cancer, despite only 9% of the survivors in 
this cohort being diagnosed with Hodgkin lymphoma in the all five-year-survivors. There were 
31 (27%) SPLs diagnosed beyond 20 years after the FPN and 15 SPLs diagnosed beyond 
attained age 40 years (Table 1). 
 
First primary neoplasm (FPN) characteristics of survivors with a SPL  
The characteristics of the 115 five-year survivors who developed a SPL are summarized in 
Table 2 by type of FPN. Among these, 39 (34%) were diagnosed with their FPN under the age 
of five years; specifically, 83% (5/6) and 75% (6/8) of SPLs occurring among neuroblastoma 
or Wilms tumor survivors were originally diagnosed before age five, respectively (Table 2). 
The median latency between the FPN and SPL was 10 years (Table 1), with the shortest delay 
noted for survivors of soft-tissue sarcoma (8 years) and leukemia (9 years). In contrast, 
survivors whose first malignancy was either Wilms tumor or retinoblastoma had the longest 
mean latency – 17 and 37 years, respectively. The median attained age at SPL diagnosis was 
20 years (Table 1), while median age at the development of SPL was highest for Hodgkin 
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lymphoma (21 years), not classifiable childhood cancers (25 years) and retinoblastoma (41 
years) survivors (Table 2).  
Overall risk of SPL 
Compared to that expected from the general population, CCSs had an almost 4-fold risk (SIR 
3·7, 95% CI 3·1–4·5) of developing an SPL, and almost eight leukemias per 100,000 person-
years (AER 7·5, 95% CI 6·0–9·2) in excess of that expected (Table 3). The cumulative 
incidence for the development of SPL steadily increased after FPN diagnosis, from 0·1% (95% 
CI 0·1–0·2) at 20 years to 0·6% (95% CI 0·4–0·9) at 50 years (Figure 1a).  
All survivors of each specific type of primary childhood cancer—except retinoblastoma and 
bone sarcoma—had both a statistically significantly increased relative (SIR) and absolute 
(AER) excess risk of developing a SPL, with the greatest excess risks among Hodgkin 
lymphoma survivors (SIR 7·9, 95% CI 4·7–12·3; AER 18·9, 95% CI 11·7–30·6) (table 3). 
However, the large excess risk for Hodgkin lymphoma survivors seen before 20 years follow-
up (SIR of 12·5) disappears with longer follow-up (SIR 1·9, 95% CI 0·2–6·8). When stratifying 
into 4 FPN tumor types (leukemia, lymphoma included also the non-Hodgkin Lymphoma 
(NHL), CNS and others), the cumulative incidence at 20 years was highest among lymphoma 
survivors (0·3%, 95% CI 0·2–0·4) (Figure 1b).  
Although SIRs appeared to be higher among survivors diagnosed in most recent decades (p-
trend=0·0002; Tables 3 & Appendix Table S4, p 4), this finding was not confirmed by 
multivariable analyses adjusted for country, sex, type of childhood cancer, age at diagnosis, 
decade of diagnosis, and years from diagnosis at exit (p-trend=0·5180; Table 4). In addition, 
we observed no significant differences in cumulative incidence of SPL among categories of 
decade of diagnosis of FPN (p=0·2797) (Figure 1c). 
SIRs decreased significantly with increasing attained age at exit (p-trend=0·0002), but were 
still 2-fold elevated beyond 30 years of age compared to the general population (Table 3). 
Similarly, the SIR declined with time since FPN diagnosis (p-trend<0·0001) but remained 
significantly elevated (SIR 2·4, 95% CI 1·6–3·4) after 20 years of follow-up (Table 3). The 
multivariable analysis revealed that SIRs varied substantially with follow-up time from FPN 
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diagnosis (p=0·0018) (Table 4). AERs were particularly high between 5-9 years of follow-up 
(AER 15·1, 95% CI 11·3–20·1) and then declined substantially to 3·8 to 4·2 between 10 to 39 
years, and then increased sharply (AER 12·7, 95% CI 4·8–33·9) beyond 40 years follow-up 
(Table 3).  
Risks of subsequent primary myeloid leukemias (SPML) and subsequent primary 
lymphoid leukemias (SPLL) 
Differences in the cumulative incidence rates of SPML and SPLL were observed (Figure 1d).  
Overall, survivors had significantly and substantially elevated risks for myeloid neoplasms, 
with a relative risk of 6-fold (SIR 5·8, 95% CI 4·6–7·1) and six myeloid leukemias per 100,000 
person-years (AER 6·3, 95% CI 5·0–8·0) in excess of that expected (Table 5). Survivors of 
each specific type of childhood cancer—except retinoblastoma and bone sarcoma—had both 
a statistically significantly increased SIR and AER for developing a SPML, though Hodgkin 
lymphoma survivors experienced the greatest SIR and AER (SIR 12·1, 95% CI 6·9–19·6; AER 
16·8, 95% CI 10·0–27·9). SPML AERs varied with age at diagnosis. Those diagnosed under 
the age of five years and over 15 years experienced an excess of four SPMLs per 100,000 
person-years, while those diagnosed at ages 5 to 14 years experienced an excess of eight to 
ten SPMLs per 100,000 person-years. Most SPMLs were diagnosed under the age of 30 years 
(81·4%) and 76·7% occurred within 20 years of FPN diagnosis.  
In contrast, the SIR was not significantly elevated for lymphocytic leukemia (SIR 1·2, 95% CI 
0·7–2·0) and the AER for developing a SPLL was only 0·3 per 100,000 person-years 
(Appendix Table S5, p 5). No significantly increased SIRs or AERs were noted for SPLLs 
when stratified by sex, FPN, age at diagnosis, decade of diagnosis, attained age at exit, nor 
years from diagnosis at exit.  
 
Discussion 
Main findings 
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In this largest ever cohort study investigating the risk of SPLs in five-year CCSs, we showed 
that the risk of developing a SPL remained elevated for at least 20 years from FPN diagnosis 
and only the risk of SPML is increased and not for SPLL. Due to the collaborative nature of 
this study, we were able to expand upon previous individual studies from the UK,8 France,6 
Italy,23 Nordic countries,19 and United States5,20 and overcome their limitations of low statistical 
power. Indeed, compared to the largest previous study investigating SPL risk in CCSs from 
the North American Childhood Cancer Survivor Study,5 we observed three-times the number 
of SPLs both overall (115 vs. 43) and beyond 15 years from FPN diagnosis (40 vs. 13). As a 
result, we provide the most robust estimates of SPL risks among CCSs to date, which 
substantially adds to the literature and will aid the long-term follow-up of CCSs.  
The overall SIR was 3·7 for a SPL, which was slightly higher than the SIR from the previous 
Nordic countries study with 30,880 childhood cancer patients diagnosed between 1943 and 
1987 (SIR of 2·8).19 However, our SIR was slightly lower than that reported in a previous CCSS 
publication with 14,358 survivors showing a 6-fold increased risk (SIR 6·3, 95% CI 4·6–8·5),5 
and two previous European papers: a British cohort of 16,422 including CCSs diagnosed 
between 1962 and 1983 who survived at least one year (SIR of 8) and the French-British 
Euro2K cohort including 4,204 3-year CCSs diagnosed between 1947 and 1986 (SIR of 7·8).8,6 
This difference could be explained, in part, by the latency of at least 5 years in the present 
study, whereas the two previous European studies began follow-up at time of FPN diagnosis, 
1-year or 3-year survival.6,8,19 Although SPL risk is mainly elevated/peaks in the first 5 years, 
as in the CCSS,5 the PanCareSurFup study includes only five-year survivors; therefore all 
SPLs occurring in the first 5 years after treatment were not considered in the present study. 
The AER ≥ 20 years in our study (AER of 4·8 events per 100,000 person-years of follow-up) 
is higher than that found in a previous analysis (5) ≥ 15 years in CCSS survivors (AER of 2 
per 100,000 person-years).  
Previous reports have indicated that the risk of SPL reaches a plateau at approximately 10 
years;9 here we reported that SIRs and AER are still increased after 10 years, so there is no 
plateau.  
Published in final edited form as: Eur J Cancer. 2019 Aug;117:71-83. doi: 10.1016/j.ejca.2019.05.013 
12 
 
Furthermore, consistent with previous studies,26-28 the highest SPL risks (SIR and AER) were 
found in Hodgkin lymphoma survivors in this study, mainly before 20 years follow-up. 
Therefore, the awareness of this risk remains crucial for survivors of Hodgkin lymphoma.29 
Statistically significant risks (SIRs or AERs) of SPL were also found after leukemia, soft-tissue 
sarcoma, CNS tumors, non-Hodgkin’s lymphoma, neuroblastoma, and Wilms tumor. 
Clinicians should be aware of these risks during long-term follow-up care of these survivors, 
given that both chemotherapy (alkylating agents and/or topoisomerase II inhibitors) and 
radiation therapy can increase the risk of SPL following treatment.5-8  
Study strengths, limitations and sensitivity analyses 
The main advantages of the current study is its large size with nearly 70,000 survivors and its 
great the range of follow-up time; as results, we were able to quantify risks of SPL several 
decade (>20 years) after FPN diagnosis; and to show that increased risk was only seen for 
SPML and not for SPLL. These had not been possible in previous papers, and thus provides 
increased reliability in our findings for clinicians and future research. However, an inherent 
limitation of large scale cohort studies with long durations of follow-up is that it is often not 
feasible to collect detailed information on exposures. Thus, the main limitation of our study is 
the lack of treatment information on cumulative radiation dose (dose to active bone marrow), 
bone marrow transplantation, family history or syndromes, and cumulative chemotherapy 
dose exposures given as treatment for the childhood cancer; as a result, we were unable to 
look specifically at the effect of treatment protocols on the risk of SPLs. To address this point, 
we are currently conducting an international pooled study of all existing cohort and case-
control studies relating to leukemia after childhood cancer (RadLeuk project). Although smaller 
in size than the current study, this study will have available cumulative doses of individual 
cytotoxics and cumulative doses of radiation to the active bone marrow for each individual 
included.7,8,20,30 Therefore, the RadLeuk study should address the risks associated with 
cumulative radiation and chemotherapeutic doses and development of SPLs. Further research 
is warranted to assess the influence of family history or syndromes, genetic predispositions, 
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genes involved in drug metabolism, and cytogenetic and molecular features, in the 
development of SPLs. Another limitation is that we did not have general population rates for 
all the countries included in this study, with only UK or Finnish rates being used for all 
countries. We have nonetheless performed SIR or AERs sensitivity analyses to determine if 
the risk estimates reported were sensitive to the general population rates applied, and these 
additional analyses revealed that excess risk estimates were very similar regardless of the 
general population rates applied (Appendix Tables S6 and S7, p 6 and 7).  
 
Conclusions 
Our findings show that increased risk was only seen for SPML and not for SPLL. We 
demonstrate also that the cumulative incidence of SPL does not reach a plateau but continues 
to increase long after five-year survival, with CCSs experiencing increased risks for SPLs 
beyond 20 years after their treatment compared to the general population. More efforts are 
needed to collect information on the long-term risk factors of SPLs in the increasingly large 
and ageing population of CCSs; such a thorough understanding of the epidemiology of SPLs 
is essential to identify patients at the highest risk of SPL. Our findings highlight the need for 
awareness by survivors and their health care providers for potentially risk related to SPL 
several decade after childhood cancer treatment. 
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Figure 1. Cumulative incidence of new subsequent leukemia diagnosed in survivors from the five-year 
survivors of childhood cancer of the largest European PCSF study. a) Whole cohort: Solid lines are calculated 
cumulative incidence values; dashed lines are 95% CIs. Cumulative incidence curves for the main type of 
childhood cancer (b), and decade of diagnosis of FPN (c), and by leukemia type (d). 
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Figure 1. Cumulative incidence of new subsequent leukemia diagnosed in survivors from the five-year survivors of childhood cancer of the largest 
European PCSF study. a) Whole cohort: Solid lines are calculated cumulative incidence values; dashed lines are 95% CIs. Cumulative incidence curves for 
the main type of childhood cancer (b), and decade of diagnosis of FPN (c), and by leukemia type (d). 
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Table 1: Characteristics of all 69,460 five-year survivors of childhood cancer of the 
European PCSF study, 115 survivors who developed a subsequent primary leukemia (SPL) 
and 7099 survivors who deceased. 
 
*Nordic countries include Finland, Iceland, Norway, Sweden, and Denmark. FPN = first primary neoplasm;  ≠Years from FPN Diagnosis = Years 
between FPN diagnosis and SPL diagnosis or date at exit. 
Factors 
All five-year 
survivors, 
No. (%) or median 
(Range) 
Person-years 
Survivors who 
developed a SLP, 
No. (%) or median 
(Range) 
Deceased survivors, 
No. (%) or median 
(Range) 
Overall 69,460 1126273 115 7099 
Country 
 
 
 
 
Nordic countries* 22836 (33%) 355831 29 (25%) 2235 (31%) 
France  3138 (5%) 83064 9 (8%) 539 (8%) 
Hungary 4885 (7%) 50100 11 (10%) 350 (5%) 
Italy 8966 (13%) 94234 9 (8%) 527 (7%) 
Netherlands 6044 (9%) 103229 13 (11%) 491 (7%) 
Slovenia 1252 (2%) 24821 3 (3%) 146 (2%) 
Switzerland 4379 (6%) 46179 7 (6%) 279 (4%) 
UK 17960 (26%) 368816 34 (30%) 2532 (36%) 
Sex 
 
 
 
 
Male 37738 (54%) 601424 68 (59%) 4125 (58%) 
Female 31722 (46%) 524848 47 (41%) 2974 (42%) 
Type of Childhood Cancer     
Wilms tumor 4756 (7%) 95878 8 (7%) 228 (3%) 
Leukemia 16595 (24%) 219900 25 (22%) 1776 (25%) 
Hodgkin lymphoma 6000 (9%) 87584 19 (17%) 692 (10%) 
Non-Hodgkin lymphoma 3350 (5%) 53752 6 (5%) 196 (3%) 
Central Nervous System 14096 (20%) 228403 22 (19%) 2338 (33%) 
Neuroblastoma 3169 (5%) 55282 6 (5%) 251 (4%) 
Retinoblastoma 2578 (4%) 60224 3 (3%) 87 (1%) 
Bone sarcoma 3147 (5%) 51767 3 (3%) 401 (6%) 
Soft-tissue sarcoma 4501 (6%) 82501 8 (7%) 453 (6%) 
Other and not classifiable 11268 (16%) 190982 15 (13%) 677 (10%) 
Age at Diagnosis of FPN     
Median (range) 7 (0-20)  8 (0-19) 8 (0-20) 
0–4 years 26793 (39%) 463318 39 (34%) 2232 (31%) 
5–9 years 15702 (23%) 255543 30 (26%) 1842 (26%) 
10–14 years 15483 (22%) 251894 34 (30%) 1890 (27%) 
15–19 years 11482 (17%) 155517 12 (10%) 1135 (16%) 
Decade of Diagnosis of FPN     
Median (range) 1986 (1940-2008)  1980 (1948-2006) 1977 (1940-2008) 
<1970 8993 (13%) 286777 24 (21%) 1989 (28%) 
1970-1979 13479 (19%) 313456 27 (23%) 2204 (31%) 
1980-1989 20900 (30%) 339267 34 (30%) 1858 (26%) 
≥ 1990 26088 (38%) 186772 30 (26%) 1048 (15%) 
Attained Age at exit 
 
 
 
 
Median (range) 28 (5-79)  20 (6-65) 20 (5-76) 
5–19 years 16243 (23%) 408724 56 (49%) 3521 (50%) 
20–29 years 22437 (32%) 389276 33 (29%) 2089 (29%) 
30–39 years 17471 (25%) 214076 11 (10%) 798 (11%) 
≥ 40 years 13309 (19%) 114196 15 (13%) 691 (10%) 
Years from FPN Diagnosis≠     
Median (range) 19 (5-67)  10 (5-50) 9 (5-63) 
5–9 years 13211 (19%) 311750 55 (48%) 3860 (54%) 
10–19 years 23083 (33%) 449578 29 (25%) 1752 (25%) 
20–29 years 17602 (25%) 236989 15 (13%) 816 (11%) 
30–39 years 10290 (15%) 96627 9 (8%) 454 (6%) 
≥ 40 years 5274 (8%) 31328 7 (6%) 217 (3%) 
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Table 2: Characteristics of 115 five-year survivors of childhood cancer of the European PCSF study who developed a subsequent primary 
leukemia (SPL) according the first primary neoplasm (FPN). 
 
No.= frequency; FPN = first primary neoplasm; SPL= subsequent primary leukemia. ≠Years from FPN Diagnosis = Years between FPN diagnosis and SPL diagnosis
 
Wilms 
tumor   
No. (%) 
Leukemia  
No. (%) 
Hodgkin 
lymphoma 
No. (%) 
Non-Hodgkin 
lymphoma  
No. (%) 
Central 
Nervous 
System No. 
(%) 
Neuroblastoma   
No. (%) 
Retinoblastoma   
No. (%) 
Bone 
sarcoma   
No. (%) 
Soft-tissue 
sarcoma  
No. (%) 
Other and 
not 
classifiable 
No. (%) 
Overall 8 25 19 6 22 6 3 3 8 15 
Age at Diagnosis 
of FPN           
Median (range) 2 (1-7) 7 (1-14) 13 (4-18) 9 (6-14) 9 (2-16) 2 (1-6) 1 (1-10) 10 (5-13) 3 (0-10) 9 (1-19) 
0–4 years 6 (75%) 9 (36%) 1 (5%) - 7 (32%) 5 (83%) 2 (67%) 1 (33%) 5 (63%) 3 (20%) 
5–9 years 2 (25%) 10 (40%) 1 (5%) 3 (50%) 5 (23%) 1 (17%) - - 3 (38%) 5 (33%) 
10–14 years - 6 (24%) 13 (68%) 3 (50%) 8 (36%) - 1 (33%) 2 (67%) - 1 (7%) 
15–19 years - - 4 (21%) - 2 (9%) - - - - 6 (40%) 
Decade of 
Diagnosis of FPN 
          
Median (range) 1975  (1954-1989) 
1986  
(1971-2000) 
1980  
(1948-1996) 
1980  
(1963-1991) 
1989  
(1957-2006) 
1980  
(1961-1997) 
1968  
(1953-1980) 
1970  
(1959-1986) 
1992  
(1966-2004) 
1968  
(1954-2001) 
<1970 2 (25%) - 4 (21%) 1 (17%) 3 (14%) 2 (33%) 2 (67%) 1 (33%) 1 (13%) 8 (53%) 
1970-1979 4 (50%) 8 (32%) 5 (26%) 2 (33%) 4 (18%) 1 (17%) - 1 (33%) 1 (13%) 1 (7%) 
1980-1989 2 (25%) 10 (40%) 8 (42%) 2 (33%) 4 (18%) 1 (17%) 1 (33%) 1 (33%) 2 (25%) 3 (20%) 
≥ 1990 - 7 (28%) 2 (11%) 1 (17%) 11 (50%) 2 (33%) - - 4 (50%) 3 (20%) 
Age at SPL 
Diagnosis 
          
Median (range) 20 (10-32) 19 (10-31) 21 (13-59) 17 (13-57) 20 (8-65) 15 (7-43) 41 (21-47) 20 (12-40) 16 (6-36) 25 (11-65) 
5–19 years 4 (50%) 14 (56%) 6 (32%) 4 (67%) 11 (50%) 4 (67%) - 1 (33%) 7 (88%) 5 (33%) 
20–29 years 3 (38%) 10 (40%) 10 (53%) - 4 (18%) - 1 (33%) 1 (33%) - 4 (27%) 
30–39 years 1 (13%) 1 (4%) 1 (5%) - 4 (18%) 1 (17%) - - 1 (13%) 2 (13%) 
≥ 40 years - - 2 (11%) 2 (33%) 3 (14%) 1 (17%) 2 (67%) 1 (33%) - 4 (27%) 
Years from FPN 
Diagnosis≠ 
          
Median (range) 17 (9-31) 9 (5-29) 9 (5-46) 10 (5-43) 10 (5-50) 10 (5-42) 37 (20-41) 10 (8-27) 8 (5-36) 13 (6-46) 
5–9 years 1 (13%) 15 (60%) 11 (58%) 3 (50%) 11 (50%) 3 (50%) - 1 (33%) 5 (63%) 5 (33%) 
10–19 years 4 (50%) 6 (24%) 6 (32%) 1 (17%) 4 (18%) 1 (17%) - 1 (33%) 2 (25%) 4 (27%) 
20–29 years 2 (25%) 4 (16%) - 1 (17%) 4 (18%) - 1 (33%) 1 (33%) - 2 (13%) 
30–39 years 1 (13%) - 1 (5%) - 1 (5%) 1 (17%) 1 (33%) - 1 (13%) 3 (20%) 
≥ 40 years - - 1 (5%) 1 (17%) 2 (9%) 1 (17%) 1 (33%) - - 1 (7%) 
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Table 3: SIRs and AERs per 100,000 person-years at risk of developing a subsequent primary leukemia (SPL) among 69,460 five-year survivors of childhood 
cancer of the European PCSF study. 
Factor 
Overall 
By years from diagnosis 
5–19 years ≥ 20 years 
O/E SIR (95% CI) AER (95% CI) O/E SIR (95% CI) AER (95% CI) O/E SIR (95% CI) AER (95% CI) 
Overall 115·0/31·0 3·7 (3·1-4·5) 7·5 (6·0-9·2) 84·0/17·9 4·7 (3·7-5·8) 8·7 (6·8-11·0) 31·0/13·1 2·4 (1·6-3·4) 4·9 (3·1-7·8) 
P-values  <·0001 0·0073  <·0001 0·0084  <·0001 0·0152 
Country          
Nordic countries¥ 29·0/10·9 2·7 (1·8-3·8) 5·1 (3·2-8·1) 20·0/5·7 3·5 (2·2-5·4) 6·1 (3·6-10·2) 9·0/5·2 1·7 (0·8-3·3) 3·1 (1·1-8·6) 
France  9·0/2·3 3·9 (1·8-7·4) 8·0 (3·8-17·2) 5·0/1·0 5·0 (1·6-11·8) 9·3 (3·5-24·7) 4·0/1·3 3·0 (0·8-7·7) 6·7 (2·0-22·2) 
Hungary 11·0/1·2 9·0 (4·5-16·1) 19·5 (10·4-36·5) 10·0/1·0 9·8 (4·7-18·0) 21·5 (11·2-41·3) 1·0/0·2 5·0 (0·1-28·1) 9·7 (1·1-86·5) 
Italy 9·0/2·3 3·9 (1·8-7·4) 7·1 (3·3-15·1) 8·0/1·8 4·5 (1·9- 8·8) 8·2 (3·7-18·0) 1·0/0·5 1·9 (0·0-10·6) 2·5 (0·1-43·8) 
Netherlands 13·0/2·6 5·0 (2·7-8·6) 10·1 (5·5-18·5) 11·0/1·8 6·2 (3·1-11·2) 12·4 (6·5-23·7) 2·0/0·8 2·5 (0·3-8·9) 4·1 (0·7-24·8) 
Slovenia 3·0/0·7 4·3 (0·9-12·4) 9·2 (2·5-33·7) 3·0/0·4 8·3 (1·7-24·2) 16·7 (5·0-55·9) 0·0/0·3 - - 
Switzerland 7·0/1·2 6·1 (2·4-12·5) 12·7 (5·6-28·5) 7·0/1·0 7·2 (2·9-14·8) 15·1 (6·8-33·5) 0·0/0·2 - - 
UK 34·0/9·9 3·5 (2·4-4·8) 6·5 (4·4-9·8) 20·0/5·4 3·7 (2·3-5·8) 6·2 (3·7-10·4) 14·0/4·5 3·1 (1·7-5·2) 7·1 (3·8-13·4) 
P for heterogeneity*  0·0393 0·0444  0·1393 0·0453   0·9183 0·7732 
Sex            
Male 68·0/18·8 3·6 (2·8-4·6) 8·2 (6·2-10·8) 47·0/11·1 4·2 (3·1-5·6) 8·8 (6·3-12·2) 21·0/7·7 2·7 (1·7-4·2) 6·9 (4·0-11·9) 
Female 47·0/12·2 3·9 (2·9-5·2) 6·6 (4·8-9·3) 37·0/6·8 5·4 (3·8-7·5) 8·6 (6·0-12·3) 10·0/5·4 1·9 (0·9-3·4) 2·7 (1·1-6·6) 
P for heterogeneity*  0·7324 0·3446  0·2561 0·9348   0·3207 0·0771 
Type of Childhood Cancer            
Wilms tumor 8·0/2·5 3·2 (1·4-6·4) 5·8 (2·5-13·3) 5·0/1·5 3·4 (1·1-7·8) 5·9 (2·1-16·7) 3·0/1·0 3·1 (0·6-8·9) 5·6 (1·4-22·2) 
Leukemia 25·0/5·4 4·7 (3·0-6·9) 8·9 (5·7-13·9) 21·0/4·2 5·0 (3·1-7·7) 9·8 (6·1-15·8) 4·0/1·2 3·4 (0·9-8·7) 5·9 (1·8-18·8) 
Hodgkin lymphoma 19·0/2·4 7·9 (4·7-12·3) 18·9 (11·7-30·6) 17·0/1·4 12·5 (7·3-20·0) 25·3 (15·4-41·5) 2·0/1·1 1·9 (0·2-6·8) 3·7 (0·5-27·7) 
Non-Hodgkin lymphoma 6·0/1·5 3·9 (1·4-8·4) 8·3 (3·3-21·0) 4·0/0·9 4·6 (1·2-11·7) 8·4 (2·8-25·5) 2·0/0·7 3·0 (0·4-10·7) 7·9 (1·4-43·6) 
Central Nervous System 22·0/6·4 3·5 (2·2-5·2) 6·8 (4·2-11·2) 15·0/3·5 4·3 (2·4-7·1) 7·6 (4·2-13·5) 7·0/2·9 2·4 (1·0-5·0) 5·4 (2·1-14·2) 
Neuroblastoma 6·0/1·5 4·1 (1·5-8·9) 8·2 (3·3-20·6) 4·0/1·0 4·1 (1·1-10·6) 8·4 (2·7-26·0) 2·0/0·5 4·0 (0·5-14·6) 7·8 (1·6-38·4) 
Retinoblastoma 3·0/1·7 1·8 (0·4-5·3) 2·2 (0·4-12·1) 0·0/0·9 - - 3·0/0·8 3·8 (0·8-11·1) 8·2 (2·2-30·6) 
Bone sarcoma 3·0/1·6 1·9 (0·4-5·6) 2·8 (0·5-14·2) 2·0/0·7 2·7 (0·3-9·9) 3·7 (0·7-21·4) 1·0/0·8 1·2 (0·0-6·6) 0·9 (0·0-124) 
Soft-tissue sarcoma 8·0/2·4 3·3 (1·4-6·4) 6·7 (2·9-15·5) 7·0/1·2 5·7 (2·3-11·8) 11·2 (4·9-25·3) 1·0/1·2 0·8 (0·0-4·6) - 
Other and not classifiable 15·0/5·7 2·6 (1·5-4·3) 4·9 (2·5-9·2) 9·0/2·8 3·3 (1·5-6·2) 5·0 (2·3-11·0) 6·0/3·0 2·0 (0·7-4·4) 4·5 (1·5-13·9) 
P for heterogeneity*  0·0550 0·0202  0·0392 0·0120   0·9256 0·9927 
Age at Diagnosis of FPN            
0–4 years 39·0/12·2 3·2 (2·3-4·4) 5·8 (4·0-8·5) 26·0/8·2 3·2 (2·1-4·7) 5·8 (3·6-9·2) 13·0/4·1 3·2 (1·7-5·5) 5·8 (3·0-11·1) 
5–9 years 30·0/6·5 4·6 (3·1-6·6) 9·2 (6·1-13·8) 25·0/3·9 6·4 (4·1-9·4) 12·1 (7·9-18·6) 5·0/2·6 1·9 (0·6-4·5) 2·9 (0·8-10·4) 
10–14 years 34·0/7·2 4·8 (3·3-6·6) 10·7 (7·3-15·6) 26·0/3·5 7·4 (4·8-10·8) 13·2 (8·7-20·0) 8·0/3·6 2·2 (0·9-4·3) 5·3 (2·1-13·6) 
15–19 years 12·0/5·1 2·3 (1·2-4·1) 4·4 (2·1-9·3) 7·0/2·3 3·0 (1·2-6·2) 4·3 (1·7-10·6) 5·0/2·8 1·8 (0·6-4·1) 4·8 (1·3-17·9) 
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Abbreviations: O – observed number of leukemia, E – expected number of leukemia, SIR- standardized incidence ratio, AER - absolute excess risk per 100,000 person-years, 95% CI- 95% confidence interval (in bold), *P for heterogeneity or P-trend 
were calculated using two-sided likelihood ratio tests within an univariable Poisson model.  ¥Nordic countries include Finland, Iceland, Norway, Sweden, and Denmark. FPN = first primary neoplasm;  ≠Years from FPN Diagnosis = Years between 
FPN diagnosis and SPL diagnosis or date at exit.
P for heterogeneity*  0·0780 0·0487  0·0059 0·0113   0·6070 0·8302 
P-trend*  0·9746 0·5241  0·1621 0·4339   0·2485 0·8047 
Decade of Diagnosis  of FPN            
<1970 24·0/10·4 2·3 (1·5-3·4) 4·7 (2·8-8·1) 8·0/2·7 3·0 (1·3-5·9) 4·5 (1·9-10·4) 16·0/7·7 2·1 (1·2-3·4) 4·9 (2·5-9·8) 
1970-1979 27·0/7·9 3·4 (2·3-5·0) 6·1 (3·9-9·5) 15·0/4·1 3·7 (2·0-6·0) 6·0 (3·3-10·9) 12·0/3·8 3·2 (1·6-5·5) 6·2 (3·1-12·3) 
1980-1989 34·0/8·1 4·2 (2·9-5·9) 7·6 (5·2-11·2) 31·0/6·5 4·7 (3·2-6·7) 8·9 (6·0-13·2) 3·0/1·5 2·0 (0·4-5·8) 2·3 (0·5-11·7) 
≥ 1990 30·0/4·7 6·4 (4·3-9·2) 13·6 (9·2-20·0) 30·0/4·6 6·5 (4·4-9·3) 13·8 (9·3-20·3) 0·0/0·0 - - 
P for heterogeneity*  0·0020 0·0066  0·1317 0·0303   0·7058 0·5400 
P-trend*  0·0002 0·0012  0·0200 0·0033   0·7007 0·6018 
Attained Age at exit            
5–19 years 56·0/10·8 5·2 (3·9-6·7) 11·1 (8·3-14·8) 56·0/10·8 5·2 (3·9-6·7) 11·1 (8·3-14·8) -  - - 
20–29 years 33·0/7·7 4·3 (3·0-6·0) 6·5 (4·4-9·6) 26·0/5·7 4·6 (3·0-6·7) 7·0 (4·6-10·9) 7·0/2·0 3·5 (1·4-7·2) 5·0 (2·1-12·0) 
30–39 years 11·0/5·3 2·1 (1·0-3·7) 2·7 (1·2-6·0) 2·0/1·5 1·4 (0·2-5·0) 0·9 (0·1-12·2) 9·0/3·9 2·3 (1·1-4·4) 3·4 (1·4-8·1) 
≥ 40 years 15·0/7·2 2·1 (1·2-3·4) 6·8 (3·4-13·8) 0·0/0·0 - - 15·0/7·2 2·1 (1·2-3·4) 6·8 (3·4-13·8) 
P for heterogeneity*  0·0017 0·0048  0·3168 0·0489   0·5227 0·4771 
P-trend*  0·0002 0·0035  0·0824 0·0058   0·2932 0·5172 
Years from FPN Diagnosis≠            
5–9 years 55·0/8·0 6·9 (5·2-9·0) 15·1 (11·3-20·1) 55·0/8·0 6·9 (5·2-9·0) 15·1 (11·3-20·1)      
10–19 years 29·0/10·0 2·9 (1·9-4·2) 4·2 (2·7-6·6) 29·0/10·0 2·9 (1·9-4·2) 4·2 (2·7-6·6)     
20–29 years 15·0/6·0 2·5 (1·4-4·1) 3·8 (2·0-7·3)    15·0/6·0 2·5 (1·4-4·1) 3·8 (2·0-7·3) 
30–39 years 9·0/4·1 2·2 (1·0-4·2) 5·1 (2·1-12·3)    9·0/4·1 2·2 (1·0-4·2) 5·1 (2·1-12·3) 
≥ 40 years 7·0/3·0 2·3 (0·9-4·8) 12·7 (4·8-33·9)    7·0/3·0 2·3 (0·9-4·8) 12·7 (4·8-33·9) 
P for heterogeneity*  <·0001 <·0001  0·0002 <·0001  0·9442 0·1334 
P-trend*  <·0001 0·0007  0·0002 <·0001  0·8160 0·0718 
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Table 4: Relative risk (RR) and relative excess risk (RER) of developing a subsequent primary leukemia 
(SPL) by demographic and treatment factors among 69,460 five-year survivors of childhood cancer of 
the European PCSF study (Multivariable analyses). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: Relative risk (RR) and relative excess risk (RER) from multivariable Poisson regression model adjusted for country, sex, type of 
childhood cancer, age at diagnosis, decade of diagnosis, and years from diagnosis. ‡P for heterogeneity or P-trend were calculated using two-sided 
likelihood ratio tests within a multivariable Poisson model.; Ref- reference category, 95% CI- 95% confidence interval. *Nordic countries include 
Finland, Iceland, Norway, Sweden, and Denmark. FPN= first primary neoplasm;  ≠Years from FPN Diagnosis = Years between FPN diagnosis and 
SPL diagnosis or date at exit. 
 
Factors RR (95% CI) RER (95% CI) 
Sex   
Male Ref Ref 
Female 1·2 (0·8-1·7) 1·0 (0·6-1·6) 
P for heterogeneity‡ 0·4328 0·9621 
Type of Childhood Cancer     
Wilms tumor Ref Ref 
Leukemia 1·1 (0·5-2·6) 0·5 (0·2-1·3) 
Hodgkin lymphoma 2·2 (0·9-5·4) 1·6 (0·5-4·7) 
Non-Hodgkin lymphoma 1·1 (0·3-3·2) 3·7 (1·1-12·8) 
Central Nervous System 1·0 (0·4-2·3) 0·8 (0·3-2·2) 
Neuroblastoma 1·2 (0·4-3·5) 2·5 (0·8-7·8) 
Retinoblastoma 0·7 (0·2-2·7) 2·3 (0·4-12·8) 
Bone sarcoma 0·5 (0·1-2·1) 2·5 (0·6- 11·6) 
Soft-tissue sarcoma 1·0 (0·4-2·8) 2·2 (0·7-6·6) 
Other and not classifiable 0·9 (0·3-2·2) 0·8 (0·3-2·5) 
P for heterogeneity‡ 0·2471 0·0005 
Age at Diagnosis of FPN   
0–4 years 1·1 (0·5-2·3) 1·8 (0·7-4·4) 
5–9 years 1·6 (0·7-3·3) 3·2 (1·2-8·1) 
10–14 years 1·7 (0·9-3·5) 2·5 (1·0-6·2) 
15–19 years Ref Ref 
P for heterogeneity‡ 0·1918 0·0542 
P-trend‡ 0·5536 0·9484 
Decade of Diagnosis of FPN   
<1970 Ref Ref 
1970-1979 1·1 (0·6-2·2) 0·9 (0·4-2·0) 
1980-1989 1·2 (0·6-2·3) 0·7 (0·3-1·5) 
≥1990 1·4 (0·7-3·0) 0·5 (0·2-1·2) 
P for heterogeneity‡ 0·8251 0·3701 
P-trend‡ 0·5180 0·1187 
Years from FPN Diagnosis≠   
5–9 years 2·1 (0·8-5·4) 1·4 (0·4-4·7) 
10–19 years 0·9 (0·3-2·4) 0·8 (0·2-2·8) 
20–29 years 0·8 (0·3-2·3) 1·1 (0·3-3·6) 
30–39 years 0·8 (0·3-2·3) 1·7 (0·5-6·1) 
≥ 40 years Ref Ref 
P for heterogeneity‡ 0·0018 0·2498 
P-trend‡ 0·0040 0·4488 
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Table 5: SIRs and AERs per 100,000 Person-Years at risk of developing a subsequent myeloid primary 
leukemia (SPLM) and relative risk (RR) and relative of developing a SPLM by demographic and 
treatment factors among 69,460 five-year survivors of childhood cancer of the European PCSF study 
(Multivariable analyses). 
 
Abbreviations: O – observed number of leukemia, E – expected number of leukemia, SIR- standardized incidence ratio, AER - absolute excess risk 
per 100,000 person-years, 95% CI- 95% confidence interval (in bold), P for heterogeneity or P-trend were calculated using two-sided likelihood ratio 
tests within an univariable Poisson model. Relative risk (RR) and relative excess risk (RER) from multivariable Poisson regression model adjusted 
for country, sex, type of childhood cancer, age at diagnosis, decade of diagnosis, and years from diagnosis. ‡P for heterogeneity or P-trend were 
calculated using two-sided likelihood ratio tests within a multivariable Poisson model.; Ref- reference category, 95%CI- 95% confidence interval. 
*Nordic countries include Finland, Iceland, Norway, Sweden, and Denmark. FPN = first primary neoplasm;  ≠Years from FPN Diagnosis = Years 
between FPN diagnosis and SPLM diagnosis or date at exit. 
Factor O/E SIR (95% CI) RR (95% CI) AER (95% CI) RER (95% CI) 
Overall 86·0/14·9 5·8 (4·6-7·1)  6·3 (5·0-8·0)  
P-values  <·0001  0·0078  
Sex         
Male 49·0/8·5 5·7 (4·3-7·6) Ref 6·7 (4·9-9·2) Ref 
Female 37·0/6·4 5·8 (4·1-8·0) 1·1 (0·7-1·7) 5·8 (4·1-8·3) 1·2 (0·7-2·1) 
P for heterogeneity  0·9757 0·6891 0·5498 0·4485 
Type of Childhood Cancer           
Wilms tumor 6·0/ 1·1 5·5 (2·0-12·0) Ref 5·1 (2·1-12·4) Ref 
Leukemia 22·0/2·3 9·6 (6·0-14·5) 1·3 (0·5-3·3) 9·0 (5·8-13·9) 0·5 (0·2-1·6) 
Hodgkin lymphoma 16·0/1·3 12·1 (6·9-19·6) 2·0 (0·7-5·7) 16·8 (10·0-27·9) 1·3 (0·3-4·8) 
Non-Hodgkin lymphoma 4·0/0·8 5·1 (1·4-13·1) 0·9 (0·2-3·2) 6·0 (2·0-17·9) 3·6 (0·7-19·3) 
Central Nervous System 16·0/3·2 5·1 (2·9-8·2) 0·9 (0·3-2·4) 5·6 (3·3-9·7) 0·8 (0·2-2·7) 
Neuroblastoma 4·0/0·6 7·0 (1·9-17·9) 1·2 (0·3-4·2) 6·2 (2·1-17·9) 1·9 (0·4-9·5) 
Retinoblastoma 0·0/0·7 - - - - 
Bone sarcoma 1·0/0·8 1·2 (0·0-6·6) 0·2 (0·0-1·8) 0·3 (0·0-41·3) 1·1 (0·1-11·3) 
Soft-tissue sarcoma 6·0/1·2 5·0 (1·9-11·0) 1·0 (0·3-3·1) 5·8 (2·4-14·3) 2·9 (0·7-12·3) 
Other and not classifiable 11·0/3·0 3·7 (1·9-6·7) 0·8 (0·3-2·2) 4·2 (2·1-8·4) 0·9 (0·3-3·2) 
P for heterogeneity  0·0421 0·2457 0·0330 0·0168 
Age at Diagnosis of FPN         
0–4 years 25·0/4·8 5·2 (3·3-7·6) 1·7 (0·7-4·2) 4·3 (2·8-6·7) 1·5 (0·5-4·6) 
5–9 years 24·0/3·2 7·4 (4·7-11·0) 2·2 (1·0-5·2) 8·1 (5·3-12·5) 3·0 (0·9-9·6) 
10–14 years 28·0/4·0 6·9 (4·6-10·0) 2·2 (1·0-4·9) 9·5 (6·4-14·2) 2·9 (1·0-8·2) 
15–19 years 9·0/2·8 3·2 (1·5-6·1) Ref 4·0 (1·8-8·8) Ref 
P for heterogeneity  0·1272 0·2192 0·0275 0·0629 
P-trend  0·5240 0·5719 0·2793 0·8119 
Decade of Diagnosis of FPN         
<1970 8·0/3·7 2·2 (0·9-4·3) Ref 2·4 (0·9-6·2) Ref 
1970-1979 15·0/3·6 4·2 (2·4-7·0) 1·6 (0·6-4·2) 4·7 (2·6-8·3) 1·9 (0·5-7·2) 
1980-1989 25·0/4·4 5·7 (3·7-8·5) 1·5 (0·6-3·9) 5·7 (3·7-8·8) 0·9 (0·2-3·7) 
≥ 1990 38·0/3·3 11·4 (8·1-15·7) 2·0 (0·7-5·3) 10·1 (7·3-14·1) 0·5 (0·1-2·0) 
P for heterogeneity  <·0001 0·5264 0·0064 0·1036 
P-trend  <·0001 0·4096 0·0006 0·0520 
Years from FPN Diagnosis≠         
5–9 years 42·0/2·6 16·0 (11·5-
21·6) 
2·6 (0·8-9·1) 12·6 (9·2-17·3) 0·5 (0·1-3·0) 
10–19 years 24·0/4·9 4·9 (3·1-7·2) 0·8 (0·2-2·9) 4·2 (2·7-6·6) 0·2 (0·0-1·6) 
20–29 years 13·0/3·8 3·4 (1·8-5·9) 0·7 (0·2-2·4) 3·9 (2·0-7·4) 0·3 (0·0-1·8) 
30–39 years 3·0/2·3 1·3 (0·3-3·9) 0·3 (0·1-1·5) 0·7 (0·1-7·5) 1·1 (0·2-8·6) 
≥ 40 years 4·0/1·3 3·1 (0·8-7·9) Ref 8·6 (2·6-28·4) Ref 
P for heterogeneity  <·0001 <·0001 <·0001 0·1056 
P-trend  <·0001 <·0001 0·0001 0·9415 
